رادار التجارب AI | ||
|---|---|---|
حالة التجربة السريرية NCT06322888 لـ سرطان الثدي، سرطان الثدي لدى الإناث هي قيد التجنيد. اطلعوا على جميع التفاصيل في عرض البطاقة الخاص برادار التجارب السريرية وأدوات اكتشاف الذكاء الاصطناعي. أو يمكنكم طرح أي سؤال هنا. | ||
تجربة واحدة تطابق معايير الفلتر
عرض البطاقة
Resistance and Aerobic Exercise for Prevention in Women With Dense Breasts (REP-D)
تفاصيل التجربة السريرية متاحة بشكل أساسي باللغة الإنجليزية. ومع ذلك، يمكن لـ 'رادار التجارب AI' أن يساعدك؛ ما عليك سوى النقر على 'وصف الدراسة' لعرض ومناقشة معلومات التجربة باللغة التي اخترتها.
التجربة السريرية NCT06322888 هي دراسة تدخُّلية لـسرطان الثدي، سرطان الثدي لدى الإناث وهي قيد التجنيد. بدأت في ١٨ رمضان ١٤٤٥ هـ مع خطة لتجنيد ٤٦ مشاركًا. يقودها Dana-Farber Cancer Institute، ومن المتوقع اكتمالها بحلول ٢٢ رجب ١٤٤٨ هـ. تم تحديث البيانات الأخيرة من ClinicalTrials.gov في ٣٠ جمادى الأولى ١٤٤٧ هـ.
الملخص
The goal of this study is to learn more about how exercise might lower the risk of developing breast cancer in women with dense breast tissue by studying changes that occur in breast tissue and blood as a result of participating in an exercise program.
The names of the study groups in this study are:
- Exercise Training Group
- Waitlist Control Group
وصف مفصل
The goal of this study is to learn more about how exercise might lower the risk of developing breast cancer by studying changes that occur in breast tissue and blood as a result of participating in an exercise program. Participants will be placed into one of two study groups: Exercise Training Group vs. Waitlist Control Group. Randomization means that a participant is put into a group by chance.
The research study procedures include screening for eligibility and baseline and end of study assessments which include: breast biopsies, assessment of physical activity habits, aerobic and strength testing, blood draws and questionnaires.
Participants randomized to the exercise group will be expected to participate in exercise sessions throughout the study. They will also be asked to complete logs of their activity.
Participants will be in this research study for up to 16 weeks.
It is expected that 46 women will take part in this study.
The Breast Cancer Research Foundation is supporting this research study by providing funding.
العنوان الرسمي
Resistance and Aerobic Exercise for Prevention in Women With Dense Breasts (REP-D)
الحالات الطبية
سرطان الثديسرطان الثدي لدى الإناثمعرّفات دراسة أخرى
- 23-676
NCT معرّف
تاريخ البدء (فعلي)
2024-03-28
آخر تحديث مُنشور
2025-11-21
تاريخ الاكتمال (المقدر)
2026-12-31
عدد المشاركين المخطط لهم
٤٦
نوع الدراسة
تدخُّلية
المرحلة
غ/م
الحالة
قيد التجنيد
الكلمات الرئيسية
Breast Cancer
Breast Cancer Female
Breast Cancer Risk
Dense breast tissue
Dense breasts
Breast Cancer Female
Breast Cancer Risk
Dense breast tissue
Dense breasts
الغرض الأساسي
وقاية
طريقة توزيع المشاركين
عشوائي
نموذج التدخل
التصميم المتوازي
التعمية
لا شيء (مفتوحة)
مجموعات/التدخلات
| مجموعة المشاركين/مجموعة | تَدَخُّل/علاج |
|---|---|
تجريبيةArm A: Exercise Intervention Participants will be randomized and will complete:
* Baseline study visit with assessments, breast biopsy, and blood draw.
* Exercise program for 12 weeks 3x weekly and exercise logs. Additional blood draw after first exercise session.
* End of study visit with assessments, breast biopsy, and blood draw. | برنامج تدريب التمارين A 12-week aerobic and resistance-training exercise intervention with a certified exercise trainer in person or virtually. FitBit activity tracker, resistance bands, hand weights, and stationary bike will be provided to participants. Hand weights will be returned at end of study. |
بدون تدخلArm B: Waitlist Control Participants will be randomized and will complete:
* Baseline study visit with assessments, breast biopsy, and blood draw.
* End of study visit with assessments, breast biopsy, and blood draw.
* Participants will be offered a complimentary 12-week exercise program after completing the study. | غ/م |
النتيجة الرئيسية
النتيجة الثانوية
| مقياس النتيجة | وصف القياس | الإطار الزمني |
|---|---|---|
Change in Irisin in Exercise Group | Change in circulating irisin at baseline, after 1st exercise session, and end of study in exercise group, and it will be compared using Wilcoxon rank-sum testing. Irisin will be measured by Parallel Reaction Monitoring in the Spiegelman Lab, using the method described by Jedrychowski. | At baseline, within 2 hours of 1st exercise session, and at week 12, up to 16 weeks |
Change in Irisin in Control Group | Change in circulating irisin at baseline and end of study in control group, and it will be compared using Wilcoxon rank-sum testing. Irisin will be measured by Parallel Reaction Monitoring in the Spiegelman Lab, using the method described by Jedrychowski. | At baseline and week 12, up to 16 weeks |
| مقياس النتيجة | وصف القياس | الإطار الزمني |
|---|---|---|
Change in Tissue Markers in Exercise Group | Immunofluorescence analysis of immune and proliferative markers from biopsies of benign breast tissue will be assessed through C-detection by indexing (CODEX) imaging for the exercise group and will be compared between treatments using Wilcoxon rank-sum testing. Imaging to be performed by the Molecular Imaging Core (MIC) at Dana-Farber Cancer Institute. | At baseline and week 12, up to 16 weeks |
Change in Tissue Markers in Control Group | Immunofluorescence analysis of immune and proliferative markers from biopsies of benign breast tissue will be assessed through C-detection by indexing (CODEX) imaging for the exercise group and will be compared between treatments using Wilcoxon rank-sum testing. Imaging to be performed by the Molecular Imaging Core (MIC) at Dana-Farber Cancer Institute. | At baseline and week 12, up to 16 weeks |
Change in Biomarkers in Exercise Group - Meso scale | Assessed by assays for inflammatory mediators and will be performed using a Meso Scale Discovery multi-plex analysis system and will be conducted by the Translational Research Laboratory at Dana-Farber Cancer Institute. | At baseline and week 12, up to 16 weeks |
Change in Biomarkers in Exercise Group - Mass cytometry | Mass cytometry (CyTOF) will be used to evaluate a panel of immune mediators and will be performed in conjunction with the Polyak Laboratory. Wilcoxon rank-sum testing will be used to compare between treatments. | At baseline and week 12, up to 16 weeks |
Change in Biomarkers in Control Group - Meso Scale | Assessed by assays for inflammatory mediators and will be performed using a Meso Scale Discovery multi-plex analysis system and will be conducted by the Translational Research Laboratory at Dana-Farber Cancer Institute. Additionally, Mass cytometry (CyTOF) will be used to evaluate a panel of immune mediators and will be performed in conjunction with the Polyak Laboratory. Wilcoxon rank-sum testing will be used to compare between treatments. | At baseline and week 12, up to 16 weeks |
Change in Biomarkers in Control Group - Mass cytometry | Mass cytometry (CyTOF) will be used to evaluate a panel of immune mediators and will be performed in conjunction with the Polyak Laboratory. Wilcoxon rank-sum testing will be used to compare between treatments. | At baseline and week 12, up to 16 weeks |
Change in Participant Weight in Exercise Group | Defined as the percent change in weight for Exercise Group from pretreatment to week 12 will be calculated, summarized, and compared using Wilcoxon rank-sum testing. | At baseline and week 12, up to 16 weeks |
Change in Participant Weight in Control Group | Defined as the percent change in weight for Control Group from pretreatment to week 12 will be calculated, summarized, and compared using Wilcoxon rank-sum testing. | At baseline and week 12, up to 16 weeks |
Change in Cardiorespiratory Fitness in Exercise Group | Assessed by VO2 max (i.e., the number of milliliters of oxygen used per kilogram of body weight in one minute (ml/kg/min)), measured using the Sub-Maximal Cycle Ergometer Test, will be calculated and compared using Wilcoxon rank-sum testing. | At baseline and week 12, up to 16 weeks |
Change in Cardiorespiratory Fitness in Control Group | Assessed by VO2 max (i.e., the number of milliliters of oxygen used per kilogram of body weight in one minute (ml/kg/min)), measured using the Sub-Maximal Cycle Ergometer Test, will be calculated and compared using Wilcoxon rank-sum testing. | At baseline and week 12, up to 16 weeks |
10-Repetition Max Test in Exercise Group | The 10-Repetition Max Test is defined as the heaviest weight a participants could lift for 10 repetitions. Change and relative percent change will be calculated and compared between treatments using Wilcoxon rank-sum testing. | At baseline and week 12, up to 16 weeks |
10-Repetition Max Test in Control Group | The 10-Repetition Max Test is defined as the heaviest weight a participants could lift for 10 repetitions. Change and relative percent change will be calculated and compared between treatments using Wilcoxon rank-sum testing. | At baseline and week 12, up to 16 weeks |
Change in Minutes of Total Exercise for Exercise Group | Change in minutes of total exercise and met hours per week (7-day par) will be calculated and compared between treatments using Wilcoxon rank-sum testing. The proportion of participants that achieve 150 minutes of exercise per week by 12 weeks will be compared using Wilcoxon rank-sum testing and Fisher's exact tests. | Up to 16 weeks |
Change in Minutes of Total Exercise for Control Group | Change in minutes of total exercise and met hours per week (7-day par) will be calculated and compared between treatments using Wilcoxon rank-sum testing. The proportion of participants that achieve 150 minutes of exercise per week by 12 weeks will be compared using Wilcoxon rank-sum testing and Fisher's exact tests. | Up to 16 weeks |
معايير الأهلية
الأعمار المؤهلة للدراسة
بالغ
العمر الأدنى للدراسة
18 Years
الجنس المؤهل
أنثى
يقبل المتطوعين الأصحاء
نعم
- Women aged 18-59
- Heterogeneously dense/extremely dense (BIRADS 3 or 4) breast tissue on mammogram within the past 12 months
- Physically inactive; engaging in <60 minutes of moderate or vigorous intensity exercise per week, as assessed by Godin Leisure Time screener
- Not pregnant or breastfeeding
- English speaking and able to read English. Investigators are only enrolling English-speaking participants to this study at this time due to the fact that investigators currently only have English-speaking exercise trainers with the proper qualifications to conduct the exercise training
- Written informed consent prior to any study-related procedures
- Self-reported inability to walk 2 blocks (at any pace)
- Prior history of breast cancer; prior DCIS is allowable as long as participant is not taking endocrine therapy and has at least 1 breast that has not been irradiated
- On oral or implantable hormonal contraceptives, postmenopausal hormone replacement therapy, a selective estrogen receptor modulator or an aromatase inhibitor; Mirena or other IUD is acceptable
- Consistent strength training in the past 3 months
- Use of weightloss drugs
- Cardiovascular, respiratory or musculoskeletal disease or joint problems that preclude moderate exercise. Examples would include unstable angina, recent myocardial infarction, oxygen-dependent pulmonary disease, and osteoarthritis requiring imminent joint replacement. Moderate arthritis that does not preclude physical activity is not a reason for ineligibility
- Psychiatric disorders or conditions that would preclude participation in the study intervention (e.g. untreated major depression or psychosis, substance abuse, severe personality disorder)
Dana-Farber Cancer InstituteBreast Cancer Research Foundationالجهة المسؤولة عن الدراسة
Jennifer A. Ligibel, MD, المحقق الرئيسي, Principal Investigator, Dana-Farber Cancer Institute
جهة اتصال مركزية للدراسة
جهة اتصال: Jennifer Ligibel, MD, 617-632-3800, [email protected]
جهة اتصال: Anna Tanasijevic, MPH, 617-632-5584, [email protected]
2 مواقع الدراسة في 1 بلدان
Massachusetts
Brigham and Women's Hospital, Boston, Massachusetts, 02115, United States
نشط (التجنيد مغلق)
Dana Farber Cancer Institute, Boston, Massachusetts, 02215, United States
Jennifer Ligibel, MD, جهة اتصال, 617-632-3800, [email protected]
Jennifer Ligibel, MD, المحقق الرئيسي
قيد التجنيد